This is a preview of subscription content, log in via an institution to check access.
Change history
08 October 2009
In the version of this article initially published, GLP-1 was incorrectly described as “glucose-lowering peptide-1”; the correct definition is “glucagon-like peptide-1.” The article also stated incorrectly that Amylin and Lilly “filed a new drug application for this drug in July…” referring to Exenatide Once Weekly. This should be corrected to “heir new drug application was accepted for review by the FDA in July.…” The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
May, M. Novo awaits green light for diabetes drug. Nat Biotechnol 27, 682–684 (2009). https://doi.org/10.1038/nbt0809-682c
Issue Date:
DOI: https://doi.org/10.1038/nbt0809-682c
- Springer Nature America, Inc.